Brief: Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections
08/01/2025 13:56
Jan 8 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA REPORTS PHASE 1 RESULTS WITH ORAL,
BROAD-ACTING
ANTIVIRAL DRUG CDI-988 FOR PROPHYLAXIS AND TREATMENT OF
NOROVIRUS, CORONAVIRUSES AND OTHER VIRAL INFECTIONS
* COCRYSTAL PHARMA INC - PLANS HUMAN CHALLENGE STUDY IN 2025
FOR
NOROVIRUS
Source text: urn:newsml:reuters.com:*:nGNXblMrfp
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway